Transgenic animals relevant to Alzheimer's disease

Neuropharmacology

Volumn 38, Issue 1, 1999, Pages 1-17

  Seabrook, Guy R ^a   Rosahl, Thomas W ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

Alzheimer's disease; Down syndrome; Hippocampal; Knockout; Transgenic

Indexed keywords

AMYLOID PRECURSOR PROTEIN; COMPLEMENTARY DNA; PRESENILIN 1;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DOWN SYNDROME; GENE CONSTRUCT; GENE MUTATION; GENETIC LINKAGE; HIPPOCAMPUS; HUMAN; KNOCKOUT GENE; LONG TERM POTENTIATION; MEMORY; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYNAPSE; TRANSGENIC ANIMAL;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEURONAL PLASTICITY; PRESENILIN-1;

EID: 0033046817     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00170-1     Document Type: Review

References (116)

1. Abel T., Martin K.C., Bartsch D., Kandel E.R. Memory suppressor genes: inhibitory constraints on the storage of long-term memory. Science. 279:1998;338-341.
2. Barger S.W., Harmon A.D. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature. 388:1997;878-881.
3. Barnes C.A. Involvement of LTP in memory: are we searching under the street light? Neuron. 15:1995;751-754.
4. Bashir Z.I., Bortolotto Z.A., Davies C.H. et al. Induction of LTP in the hippocampus needs synaptic activation of glutamate metabotropic receptors. Nature. 363:1993;347-350.
5. Behringer R. Supersonic congenics? Nat. Genet. 18:1998;108.
6. Blacker D., Wilcox M.A., Laird N.M. et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat. Genet. 19:1998;357-360.
7. Bliss T., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 361:1993;31-39.
8. Bolshakov V.Y., Siegelbaum S.A. Postsynaptic induction and presynaptic expression of hippocampal long-term depression. Science. 264:1994;1148-1152.
9. Bonkale W.L., Winblad B., Ravid R., Cowburn R.F. Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease. Neurosci. Lett. 187:1995;5-8.
10. Borchelt D.R., Thinakaran G., Eckman C.B. et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron. 17:1996;1005-1013.
11. Borchelt D.R., Parent A.R., Jenkins N.A., Copeland N.G., Price D.G., Linden D.J., Sisodia S.S. Alteration of long-term synaptic plasticity in CA1 hippocampus of transgenic mice expressing FAD-linked presenilin-1. Soc. Neurosci. Abstr. 23(2):1997;1176.
12. Borchelt D.R., Ratovitski T., van Lare J. et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 19:1997;939-945.
13. Calhoun M.E., Wiederhold K.-H., Abramowski D., Phinney A.L., Probst A., Sturchler-Perriat C., Staufenbiel M., Sommer B., Jucker M. Neuron loss in APP transgenic mice. Nature. 395:1998;755-756.
14. Carlson G.A., Borchelt D.R., Dake A. et al. Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. Hum. Mol. Genet. 6(11):1997;1951-1959.
15. Chapman P.F., Irizarri M.C., Nilsen S., Hyman B.T., Hsiao K.K. Abnormal synaptic transmission in aged APP transgenic mice. J. Physiol. (Lond.). 501:1997;95P.
16. Chen C., Tonegawa S. Molecular genetic analysis of synaptic plasticity, activity-dependent neural development, learning, and memory in the mammalian brain. Annu. Rev. Neurosci. 20:1997;157-184.
17. αΔ--mice. Science. 279:1998;867-869.
18. Citron M., Westway D., Xia W. et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat. Med. 3:1997;67-72.
19. B autoreceptors in rat hippocampus. J. Physiol. (Lond.). 496:1996;451-470.
20. Davies C.H., Starkey S.J., Pozza M., Collingridge G.L. GABA autoreceptors regulate the induction of LTP. Nature. 349:1991;609-611.
21. Davis J.A., Naruse S., Chen H. et al. An Alzheimer's disease-linked PS1 variant rescues the developmental abnormalities of PS1-deficient embryos. Neuron. 20:1998;603-609.
22. Dawson, G.R., Seabrook, G.R., Zheng, H., et al. (1998). Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the β-amyloid precursor protein. Neuroscience 89.
23. De Leon M.J., Convit A., DeSanti S. et al. Contribution of structural neuroimaging to the early diagnosis of Alzheimer's disease. Int. Psychogeriatr. 9:1997;183-190.
24. De Strooper B., Saftig P., Craessaerts K. et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 391:1998;387-390.
25. Duff K., Eckman C., Zehr C. et al. Increased amyloid-β1-42(43) in the brains of mice expressing mutant presenilin 1. Nature. 383:1996;710-713.
26. Ebly E.M., Parhad I.M., Hogan D.B., Fung T.S. Prevalence and types of dementia in the very old: results from the Canadian Study of Health and Aging. Neurology. 44:1994;1593-1600.
27. Friedland R.P. Alzheimer's disease: clinical features and differential diagnosis. Neurology. 43:1993;S45-S52.
28. Folkesson, R., Kosciessa, U., Xiao-Li, T., et al., 1997. Expression of the 650 kb genomic human APP gene in transgenic rats with the Swedish Alzheimer mutation, Soc. Neurosci. Abstr. 23: 636.1.
29. Furth P.A., St. Onge L., Boger H. et al. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc. Natl. Acad. Sci. USA. 91:1994;9302-9306.
30. Games D., Adams D., Alessandrini R. et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 373:1995;523-527.
31. Gerlai R. Gene targeting studies of mammalian behavior: is it the mutation or the background genotype? Trends Neurosci. 19:1996;177-180.
32. Geula C., Wu C.-K., Saroff D., Lorenzo A., Yuan M., Yankner B.A. Aging renders the brain vulnerable to amyloid β-protein neurotoxicity. Nat. Med. 4:1998;827-831.
33. Giese K.P., Fedorov N.B., Filipkowski R.K., Silva A.J. Autophosphorylation at Thr286 of the α-calcium-calmodulin kinase II in LTP and learning. Science. 279:1998;870-873.
34. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120:1984;885-890.
35. Goate A., Chartier-Harlin M.-C., Mullan M. et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 349:1991;704-706.
36. Goedert M., Jakes R., Spillantini M.G., Hasegawa M., Smith M.J., Crowther R.A. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature. 383:1996;550-553.
37. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA. 89:1992;5547-5551.
38. Haass C., Selkoe D.J. A technical KO of amyloid-β peptide. Nature. 391:1998;339-340.
39. Haass C., Lemere C.A., Capell A. et al. The Swedish mutation causes early-onset Alzheimer's disease by beta secretase cleavage within the secretory pathway. Nat. Med. 1:1995;1291-1296.
40. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20(4):1997;154-159.
41. Holcomb L., Gordon M.N., McGowan E. et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4(1):1998;97-100.
42. Hsiao K., Borchelt D.R., Olson K. et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor protein. Neuron. 15:1995;1203-1218.
43. Hsiao K., Chapman P., Nilsen S. et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
44. Irizarry M.C., Soriano F., McNamara M., Page K.J., Schenck D., Games D., Hyman B.T. Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 17:1997;7053-7059.
45. Johnson-Wood K., Lee M., Motter R. et al. Amyloid precursor protein processing and Aβ1-42 deposition in a transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 94:1997;1550-1555.
46. Kammesheidt A., Boyce F.M., Spanoyannis A.F. et al. Deposition of β/A4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxy-terminal fragment of the Alzheimer amyloid precursor protein. Proc. Natl. Acad. Sci. USA. 89:1992;10857-10861.
47. Kang J., Lemaire H.G., Unterbeck A. et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 325:1987;733-736.
48. Khatchaturian Z.S. Diagnosis of Alzheimer's disease. Arch. Neurol. 42:1985;1097-1105.
49. LaFerla F.M., Tinkle B.T., Bieberich C.J., Haudenschild C.C., Jay G. The Alzheimer's Aβ peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat. Genet. 9:1995;21-29.
50. Lamb B.T., Call L.M., Slunt H.H. et al. Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. Hum. Mol. Genet. 6(9):1997;1535-1541.
51. Lautenschlager N.T., Cupples L.A., Rao V.S. et al. Risk of dementia among relatives pf Alzheimer disease patients in the MIRAGE study: what is in store for the old? Neurology. 46:1996;641-650.
52. Levy-Lahad E., Wasco W., Poorkaj P. et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 269:1995;973-977.
53. Lichtenthaler S.F., Ida N., Multhaup G., Masters C.L., Beyreuther K. Mutations in the transmembrane domain of APP altering γ-secretase specificity. Biochemistry. 36:1997;15396-15403.
54. Loring J.F., Paszty C., Rose A. et al. Rational design of an animal model for Alzheimer's disease: introduction of multiple human genomic transgenes to reproduce AD pathology in rodent. Neurobiol. Aging. 17(2):1996;173-182.
55. Malenka R., Nicoll R.A. NMDA-receptor-dependent synaptic plasticity: multiple forms and mechanisms. Trends Neurosci. 16:1993;521-527.
56. Markel P., Shu P., Ebeling C., Carlson G.A., Nagle D.L., Smutko J.S., Moore K.J. Theoretical and empirical issues for marker-assisted breeding of congenic mouse strains. Nat. Genet. 17:1997;280-284.
57. Masliah E., Sisk A., Mallory M., Mucke L., Schenk D., Eames D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F β-amyloid precursor protein and Alzheimer's Disease. J. Neurosci. 16:1996;5795-5811.
58. Mayford M., Wang J., Kandel E.R., O'Dell T. CaMKII regulates the frequency-response function of hippocampal synapses for the production of both LTD and LTP. Cell. 81:1995;891-904.
59. Mayford M., Bach M.E., Huang Y.-Y., Wang L., Hawkins R.D., Kandel E.R. Control of memory formation through regulated expression of a CaMKII transgene. Science. 274:1996;1678-1683.
60. McHugh T.J., Blum K.I., Tsien J.Z., Tonegawa S., Wilson M.A. Impaired hippocampal representation of space in CA1-specific NMDAR1 knockout mice. Cell. 87:1996;1339-1349.
61. Meyer M.R., Tschanz J.T., Norton M.C., Welsh-Bohmer K.A., Steffens D.C., Wyse B.W., Bretner J.C.S. APOE genotype predicts when-not whether-one is predisposed to develop Alzheimer's disease. Nat. Genet. 19:1998;321-322.
62. Milward E.A., Papadopoulos R., Fuller S.J., Moir R.D., Small D., Beyreuther K., Masters C.L. The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron. 9:1992;129-137.
63. Moechars D., Lorent K., DeStrooper B., Dewacher I., Van Leuven F. Expression in brain of amyloid precursor protein mutated in the α-secretase site causes disturbed behaviour, neuronal degeneration and premature death in transgenic mice. EMBO J. 15:1996;1265-1274.
64. Moran P.M., Higgins L.S., Cordell B., Moser P.C. Age-related learning deficits intransgenic mice expressing the 751-amino acid isoform of human β-amyloid precursor protein. Proc. Natl. Acad. Sci. USA. 92:1995;5341-5345.
65. Muller, U., Gajic, V., Hainsellner, J., et al., 1997. Transgenic models to define the physiological role of proteins of the APP-family. Soc. Neurosci. Abstr. 729.4.
66. Nalbantoglu J., Tirado-Santiago G., Lahsaini A. et al. Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature. 387:1997;500-505.
67. Neve R.L., Robakis N.K. Alzheimer's disease: a re-examinaton of the amyloid hyothesis. Trends Neurosci. 21(1):1998;15-19.
68. Oster-Granite M.L., McPhie D.L., Greenan J., Neve R.L. Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. J. Neurosci. 16:1996;6732-6741.
69. Perez R.G., Zheng H., Van der Ploeg L.H.T., Koo E.H. The β-amyloid precursor protein of Alzheimer's disease enahnces neuron viability and modulates neuronal polarity. J. Neurosci. 17(24):1997;9407-9414.
70. Pericak-Vance M.A., Gaskell P.C. Jr., Yamaoka L.H. et al. Linkage studies in familial Alzheimer's disease: evidence for chromosome 19 linkage. Am. J. Hum. Genet. 48:1991;1034-1050.
71. Phinney, A.L., Calhoun, M.E., Wolfer, D.P., Lipp, H.-P., Zheng, H., Jucker, M., 1998. Aged APP-null mice exhibit a learning impairment which is not mediated by a loss of hippocampal neuron or synaptic bouton number. Neurosci. (in press).
72. Qian S., Jiang P., Guan X-M. et al. Mutant human presenilin 1 protects presenilin 1 null mouse against embryonic lethality and elevates Aβ1-42/43 production. Neuron. 20:1998;611-617.
73. Qui W.Q., Ferreira A., Miller C., Koo E.H., Selkoe D.J. Cell surface β-amyloid precursor protein stimulates neurite outgrowth of hippocampal neurons in an isoform dependent manner. J. Neurosci. 15:1995;2157-2167.
74. Reaume A.G., Howland D.S., Trusko S.P. et al. Enhanced amyloidogenic processing of the β-amyloid precursor protein in gene-targted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" Aβ sequence. J. Biol. Chem. 271(38):1996;23380-23388.
75. Reeves R.H., Irving N.G., Moran T.H. et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet. 11:1995;177-184.
76. Rogaev E., Sherrington R., Rogaev E.A. et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 376:1995;775-778.
77. Rogers S.L., Doody R.S., Mohs R.C., Friedhoff L.T. Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch. Intern. Med. 158:1998;1021.
78. Ropers, H.H., Pericak-Vance, M.A. Report of the committee on genetic constitution of chromosome 19. Hum. Gene Mapp. 11(1991); Cytogenet. Cell Genet. 58, 751-784.
79. Ropers, H.H., Pericak-Vance, M.A. Report of the committee on genetic constitution of chromosome 19. Hum. Gene Mapp. 11(1991); Cytogenet. Cell Genet. 58, 751-784.
80. Rotenberg A., Mayford M., Hawkins R.D., Kandel E.R., Muller R.U. Mice expressing activated CaMKII lack low frequency LTP and do not form stable place cells in the CA1 region of the hippocampus. Cell. 87:1996;1351-1361.
81. Roth G.S., Joseph J.A., Mason R.P. Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. Trends Neurosci. 18:1995;203-206.
82. Sabbagh M.N., Galasko D., Thal L.J. Amyloid and treatment opportunities for Alzheimer's disease. Alzheimer's Dis. Rev. 3:1998;1-19.
83. Saitoh T., Sundsmo M., Roch J-M., Kimura N., Cole G., Schenck D. Secreted form of amyloid β protein precursor is involved in the growth regulation of fibroblasts. Cell. 58:1989;615-622.
84. Schubert D., Jin L-W., Saitoh T., Cole G. The regulation of amyloid β protein precursor secretion and its modulatory role in cell adhesion. Neuron. 3:1989;689-694.
85. Schwenk F., Baron U., Rajewsky K. A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res. 23:1995;5080-5081.
86. Scoville W.B., Milner B. Loss of recent memory after bilateral hippocampal lesions. J. Neurol. Neurosurg. Pyschiatry. 20:1957;11-21.
87. A receptor benzodiazepine site ligands. Neuropharmacology. 36(6):1997;823-830.
88. Seabrook, G.R., Smith, D.W., Bowery, B.J., et al., 1999. Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology (in press).
89. Selkoe D.J. Alzheimer's disease: genotypes, phenotype, and treatments. Science. 275:1997;630-631.
90. Shen J., Bronson R.T., Chen D.F., Xia W., Selkoe D.J., Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell. 89:1997;629-639.
91. Sherrington R., Rogaev E.I., Liang Y. et al. Cloning of a gene bearing missense mutations in early onset familial Alzheimer's disease. Nature. 375:1995;754-760.
92. Shimohama S., Matsushima H. Signal transduction mechanisms in Alzheimer disease. Alzheimer's Dis. Assoc. Disord. 9:1995;15-22.
93. Siarey R.J., Stoll J., Rapoport S.I., Galdzicki Z. Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down syndrome. Neuropharmacology. 36:1997;1549-1554.
94. Silva A.J., Stevens C.F., Tonegawa S., Wang Y. Deficient hippocampal long-term potentiation in α-calcium calmodulin kinase II mutant mice. Science. 257:1992;201-206.
95. Silva A.J., Paylor R., Wehner J.M., Tonegawa S. Impaired spatial learning in α-calcium calmodulin kinase II mutant mice. Science. 257:1992;206-211.
96. Silva A.J., Simpson E.M., Takahashi J.S. et al. Banbury conference on genetic background in mice. Mutant mice and neuroscience: recommendations concerning genetic background. Neuron. 19:1997;755-759.
97. Sirinathsinghji D.J.S. Transgenic models of Alzheimer's disease. Curr. Res. Alzheimer's Dis. 3:1998;47-56.
98. Slunt H.H., Thinakaran G., Lee M.K., Sisodia S.S. Nucleotide sequence of the chromosome 14-encoded S182 cDNA and revised secondary structure prediction. Int. J. Exp. Clin. Invest. 2:1995;188-190.
99. Smith D.J., Stevens M.E., Sudanagunta S.P. et al. Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associatd with Down's syndrome. Nat. Genet. 16:1997;28-36.
100. Stevens C.F. Spatial learning and memory: the beginning of a dream. Cell. 87:1996;1147-1148.
101. Sturchler-Pierrat C., Abramomski D., Duke M. et al. Two amyloid precursor protein transgenic mouse models with Alzheimer's disease-like pathology. Proc. Natl. Acad. Sci. USA. 94:1997;13287-13292.
102. Suzuki N., Cheung T.T., Cai X.-D. et al. An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (βAPP717) mutants. Science. 264:1994;1336-1340.
103. Teller J.K., Russo C., DeBusk L.M. et al. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nat. Med. 2:1996;93-95.
104. Tsien J.Z., Chen D.F., Gerber D. et al. Subregion- and cell type-restricted gene knockout in mouse brain. Cell. 87:1996;1317-1326.
105. Tsien J.Z., Huerta P.T., Tonegawa S. The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell. 87:1996;1327-1338.
106. von Koch C.S., Zheng H., Chen H., Trumbauer M., Thinakaran G., van der Ploeg L.H.T., Sisodia S.S. Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice. Neurobiol. Aging. 18(6):1997;661-669.
107. Wakabayashi K., Honer W.G., Masliah E. Synapse alterations in the hippocampal-entorhinal formation in Alzheimer's disease with and without Lewy body disease. Brain Res. 667:1994;24-32.
108. Wallace M.A. Effects of Alzheimer's disease-related beta amyloid protein fragments on enzymes metabolizing phosphoinositides in brain. Biochim. Biophys. Acta. 1227:1994;183-187.
109. Weisgraber K.H., Pitas R.E., Mahley R.W. Lipoproteins, neurobiology, and Alzheimer's disease: structure and function of apolipoprotein E. Curr. Opin. Struct. Biol. 4:1994;507-515.
110. Whittington M.A., Traub R.D., Jefferys J.G. Synchronized oscillations in interneuron networks driven by metabotropic glutamate receptor activation. Nature. 373:1995;612-615.
111. Wisniewski T., Golabek A., Matsubara E., Ghiso J., Frangione B. Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem. Biophys. Res. Commun. 192:1993;359-365.
112. Wong P.C., Zheng H., Chen H. et al. Presenilin 1 is required for Notch 1 and Dll 1 expression in the paraxial mesoderm. Nature. 387:1997;288-292.
113. Yankner B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 16:1996;921-932.
114. Yasuda R.P., Ikonomovic M.D., Sheffield R., Rubin R.T., Wolfe B.B., Armstrong D.M. Reduction of AMPA-selective glutamate receptor subunits in the entorhinal cortex of patients with Alzheimer's disease pathology: a biochemical study. Brain Res. 678:1995;161-167.
115. Zheng H., Jiang M., Trumbauer M. et al. amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell. 81:1995;525-531.
116. Zola-Morgan S., Squire L.R., Amaral D.G. Human amnesia and the medial temporal region: enduring memory impairment following a bilateral lesion limited to the field CA1 of the hippocampus. J. Neurosci. 6:1986;2950-2967.